Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies
The coronavirus disease 2019 ( COVID-19 ) virus, emerged in December 2019, has spread rapidly, with cases now confirmed in multiple countries.
As of February 16, 2020, the virus has caused 70,548 infections and 1,770 deaths in mainland China and 413 infections in Japan.
A great deal of effort has been made to find effective drugs against the virus in China.
On February 17, 2020, the State Council of China held a news briefing indicating that Chloroquine phosphate, an old drug for treatment of malaria, had demonstrated marked efficacy and acceptable safety in treating COVID-19 associated pneumonia in multicenter clinical trials conducted in China.
In the early in vitro studies, Chloroquine was found to block COVID-19 infection at low-micromolar concentration, with a half-maximal effective concentration ( EC50 ) of 1.13 μM and a half-cytotoxic concentration ( CC50 ) greater than 100 μM.
A number of subsequent clinical trials have been quickly conducted in China to test the efficacy and safety of Chloroquine or Hydroxychloroquine in the treatment of COVID-19 associated pneumonia in more than 10 hospitals in Wuhan, Jingzhou, Guangzhou, Beijing, Shanghai, Chongqing, and Ningbo.
Thus far, results from more than 100 patients have demonstrated that Chloroquine phosphate is superior to the control treatment in inhibiting the exacerbation of pneumonia, improving lung imaging findings, promoting a virusnegative conversion, and shortening the disease course according to the news briefing.
Severe adverse reactions to Chloroquine phosphate were not noted in the aforementioned patients.
Given these findings, a conference was held on February 15, 2020; participants including experts from government and regulatory authorities and organizers of clinical trials reached an agreement that Chloroquine phosphate has potent activity against COVID-19.
The drug is recommended for inclusion in the next version of the Guidelines for the Prevention, Diagnosis, and Treatment of Pneumonia Caused by COVID-19 issued by the National Health Commission of the People's Republic of China.
Chloroquine is used to prevent and treat malaria and is efficacious as an anti-inflammatory agent for the treatment of rheumatoid arthritis and lupus erythematosus.
Studies have revealed that it also has potential broad-spectrum antiviral activities by increasing endosomal pH required for virus/cell fusion, as well as interfering with the glycosylation of cellular receptors of SARS-CoV.
The anti-viral and anti-inflammatory activities of Chloroquine may account for its potent efficacy in treating patients with COVID-19 pneumonia.
In conclusion, Chloroquine is a cheap and safe drug that has been used for more than 70 years.
In light of the urgent clinical demand, Chloroquine phosphate is recommended to treat COVID-19 associated pneumonia in larger populations in the future. ( Xagena )
Gao J et al, Biosci Trends 2020; Online ahead of print
Resected stage III melanoma with BRAF mutations: 5-year follow-up of adjuvant Dabrafenib plus Trametinib - Findings from the COMBI-AD study
Data from the five-year analysis featuring extended follow-up from the phase III COMBI-AD study have confirmed that 12 months of...
Efficacy and safety of Pembrolizumab plus chemotherapy to Pembrolizumab monotherapy: a consecutive analysis of NSCLC patients with high PD-L1 expression
There has been an only indirect comparison between Pembrolizumab ( Keytruda ) and Pembrolizumab plus chemotherapy in patients with non-small...
Primary Ipilimumab / Nivolumab immunotherapy followed by adjuvant Nivolumab in locally advanced or oligometastatic melanoma: preliminary results
The aim of neo-adjuvant therapy in locally advanced or oligometastatic melanoma is to facilitate radical resection, improve outcomes and undertake...
ALEX study: updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer
The ALEX study has demonstrated significantly improved progression-free survival ( PFS ) with Alectinib ( Alecensa ) versus Crizotinib (...
In the absence of effective vaccines and with limited therapeutic options, convalescent plasma is being collected across the globe for...
The mRNA-1273 vaccine for SARS-CoV-2 is tolerable and immunogenic in older adults. Data on prolonged immunogenicity and effectiveness in preventing severe...
Ayvakyt for the treatment of adults with unresectable or metastatic PDGFRA D842V mutant gastrointestinal stromal tumors, approved by European Commission
The European Commission ( EC ) has granted conditional marketing authorization to Ayvakyt ( Avapritinib ) as a monotherapy for...
FDA has approved Ayvakit, the first targeted therapy to treat a rare mutation in patients with gastrointestinal stromal tumors
The FDA ( U.S. Food and Drug Administration ) has approved Ayvakit ( Avapritinib ) for the treatment of adults...
European Commission has approved expanded use of Erleada for treatment of patients with metastatic hormone-sensitive prostate cancer
The European Commission ( EC ) has granted marketing authorisation for the expanded use of Erleada ( Apalutamide ) to...